<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790660</url>
  </required_header>
  <id_info>
    <org_study_id>1941-CL-0016</org_study_id>
    <nct_id>NCT00790660</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.</brief_title>
  <official_title>A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Multiple Dose Study to Assess the Safety and Tolerability of ASP1941 in Adult Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to assess safety and tolerability of ASP1941 compared to placebo in
      adult subjects with type 2 diabetes mellitus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial includes a two week washout period before entering the treatment period for subjects on
      oral anti-diabetic medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2008</start_date>
  <completion_date type="Actual">March 6, 2009</completion_date>
  <primary_completion_date type="Actual">March 6, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of safety through clinical safety labs and adverse events</measure>
    <time_frame>6 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of routine PK and PD parameters</measure>
    <time_frame>6 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>ASP1941 Lowest Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP1941 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP1941 Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP1941 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1941</intervention_name>
    <description>Oral</description>
    <arm_group_label>ASP1941 Medium Dose</arm_group_label>
    <arm_group_label>ASP1941 Low Dose</arm_group_label>
    <arm_group_label>ASP1941 High Dose</arm_group_label>
    <arm_group_label>ASP1941 Lowest Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of type 2 diabetes mellitus

          -  HbA1c value between 7.0 and 10.0%

          -  Body mass index between 20 and 45 kg/m2

        Exclusion Criteria:

          -  Established diagnosis of type 1 diabetes mellitus

          -  Serum creatinine &gt; upper limit of normal range

          -  Proteinuria (microalbumin/creatinine ratio &gt; 300 mg/g)

          -  Urinary tract infection

          -  Severe uncontrolled Hypertension

          -  Significant renal, hepatic or cardiovascular disease

          -  HIV Positive

          -  History of drug or alcohol abuse/dependency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/study.aspx?ID=3</url>
    <description>Link to results on the Astellas Clinical Study Results website.</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2008</study_first_submitted>
  <study_first_submitted_qc>November 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <disposition_first_submitted>February 26, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 26, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 1, 2010</disposition_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP1941</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

